Open an account

Inovio Pharmaceuticals

INO · NASDAQ

$1.01+$0.01 (+1.00%)TodayMarket closed ·
Prev close $1.00

About INO

Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. The company is headquartered in Plymouth Meeting, Pennsylvania and currently employs 112 full-time employees. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.

Employees
112
Headquarters
Plymouth Meeting, Pennsylvania
Listed
Dec 8, 1998
Sector
Health Care
Industry
Biotechnology
Website
inovio.com

INO key statistics

Market cap
104.43M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
2.90M
Volume
10.81M
Open price
$0.9981
High today
$1.06
Low today
$0.99
52 Week high
$2.72
52 Week low
$0.5632

Inovio Pharmaceuticals (INO) at a glance

As of Oct 20, 2026, Inovio Pharmaceuticals (INO) shares are priced at $1.01, giving the company a market cap of 104.43M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.99 and $1.06. The current price is 2.0% above the day's low and 4.7% below its high.

Volume so far is 10.81M shares, above the average of 2.90M shares a day.

Over the past year Inovio Pharmaceuticals has ranged from $0.5632 to $2.72, and now sits 21% of the way up that range.

Inovio Pharmaceuticals met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported -$0.07 per share against an estimate of -$0.2188.

The average analyst price target is $3.23, 219.8% above the current price, from 3 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

67%of 3 analyst ratings say Buy
  • Buy66.7%
  • Hold33.3%
  • Sell0.0%
Price target · 4 analystsAvg $3.23
Low
$2.53
Now
$1.01
High
$4.20

INO earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 43.4% on average.

  1. Q3 FY24: reported -$0.89 per share against an estimate of -$1.16
  2. Q4 FY24: reported -$0.60 per share against an estimate of -$0.8454
  3. Q1 FY25: reported -$0.41 per share against an estimate of -$0.7454
  4. Q2 FY25: reported -$0.61 per share against an estimate of -$0.6153
  5. Q3 FY25: reported -$0.87 per share against an estimate of -$0.4274
  6. Q4 FY25: reported $0.06 per share against an estimate of -$0.3614
  7. Q1 FY26: reported -$0.28 per share against an estimate of -$0.3535
  8. Q2 FY26: reported -$0.07 per share against an estimate of -$0.2188

INO news

  • 12 Health Care Stocks Moving In Tuesday's After-Market Session

  • Press releasePRNewswire

    INOVIO Announces Favorable Judgment in Litigation with VGXI, Inc. and GeneOne Life Science

  • Press releasePRNewswire

    INOVIO to Participate in Upcoming Investor Conferences

  • World Health Organization Director General Determined That The Ebola Epidemic In DRC Still Meets Criteria Of Public Health Emergency Of International Concern, But Not Those Of A Pandemic Emergency

  • Press releasePRNewswire

    INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights

  • Press releasePRNewswire

    INOVIO to Report Second Quarter Financial Results on August 12, 2026

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • Avi Kapoor

    Nasdaq Surges Over 600 Points; Microsoft Shares Jump After Upbeat Q4 Results

Similar companies

Companies in the same industry as Inovio Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.